Articles tagged "HLA antibodies"

2019 American Transplant Congress
Comparing Antibody-Mediated Rejection with or without Detectable DSA: Similar Pathology and Similar Poor Prognosis
G. Einecke¹, J. Reeve², P. F. Halloran³
¹Dpt. of Nephrology, Hannover Medical School, Hannover, Germany, ²Dpt. of Laboratory Medicine and Pathology and Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada, ³Dpt. of Nephrology and Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada
*Purpose: Banff guidelines require the detection of donor-specific antibodies (DSA) in addition to microvascular inflammation (MVI) for a diagnosis of antibody-mediated rejection (ABMR), but MVI…
2019 American Transplant Congress
Impact of HLA-DR Matching on HLA-DQ Matching Status and the Development of Anti-HLA-DQ De Novo DSA under Calcineurin Inhibitor or Belatacept Immunosuppression
V. Jucaud¹, H. Gebel², R. Bray², M. Polinsky³, M. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Emory University, Atlanta, GA, ³Bristol-Myers Squibb, Princeton, NJ
*Purpose: De novo donor-specific HLA antibodies (dnDSA) that develop after kidney transplantation target more frequently allo-HLA-DQ antigens in comparison to other allo-HLA antigens. Yet, organ…
2019 American Transplant Congress
Endothelial Cells Do Not Regulate Expression of CD46, CD55 and CD59 in the Presence of Anti-HLA Class I and 11 Antibodies
A. Babu¹, T. Pham², M. Hamdorf², V. Jucaud², M. Everly², S. Daga³, D. Mitchell⁴
¹Transplant Institute, Henry Ford Hospitals, Detroit, MI, ²Terasaki Research Institute, Los Angeles, CA, ³University of Warwick, Coventry, United Kingdom, ⁴Medical Sciences, University of Warwick, Coventry, United Kingdom
*Purpose: Anti-HLA antibodies, both pre-formed and de novo are associated with worse graft survival. Complement activation is an important mechanism of antibody mediated immunological injury.…
2019 American Transplant Congress
Association between Respiratory Virus Infections and the Development of De Novo HLA Donor-Specific Antibodies in Lung Transplant Recipients
M. I. Ali, J. Hata, J. Mallea, M. Elrefaei
Mayo Clinic, Jacksonville, FL
*Purpose: The detection of de novo donor-specific anti-HLA antibodies (DSA) post lung transplant have been associated with significantly increased risk for antibody-mediated rejection (AMR) and…
2019 American Transplant Congress
Vaccination And Allosensitization In Solid Organ Transplant Candidates
L. Lourenco¹, K. B. Bain², L. Bowman³, D. C. Brennan⁴, G. A. Ewald⁵, R. R. Hachem⁶
¹Pharmacy, University of Chicago Medicine, Chicago, IL, ²Pharmacy, Barnes-Jewish Hospital, St. Louis, MO, ³Pharmacy, Tampa General Hospital, Tampa, FL, ⁴Internal Medicine, The Johns Hopkins School of Medicine, Baltimore, MD, ⁵Heart Failure and Heart Transplantation, Washington University School of Medicine, St. Louis, MO, ⁶Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, MO
*Purpose: Clinical practice guidelines recommend vaccinating patients awaiting solid organ transplantation (SOT) against vaccine-preventable infections, but there is little evidence to suggest that vaccination reduces…
2019 American Transplant Congress
Anti-HLA Antibodies Are Associated with Deterioration in Long-Term Renal Function Independently of Donor Specificity
T. Mueller¹, P. Cippa², R. van Breemen¹, S. von Moos¹
¹Universityspital Zurich, Zurich, Switzerland, ²Ospedale Regionale di Lugano Civico, Lugano, Switzerland
*Purpose: Donor-specific antibodies (DSA) negatively impact graft survival, the clinical relevance of non-donor-specific anti-HLA antibodies (NDSA) is unclear. Hence, the purpose of our study is…
2019 American Transplant Congress
The Effect Of Exclusive Virtual Crossmatch To Allocate Deceased Donor Kidney Transplant On Cold Ischemia Time And Acute Rejection
E. Abuhelaiqa¹, M. Alkadi¹, S. Thappy¹, S. Saleh², J. Mahmoud³, M. Jarman³, O. Fituri¹, M. Elkhalifa⁴, J. Wadström³, H. Al-Malki¹
¹Medicine-Nephrology, Hamad Medical Corporation, Doha, Qatar, ²Histocompatibility & Immunogenetics Laboratory,, Hamad Medical Corporation, Doha, Qatar, ³Surgery-Transplant, Hamad Medical Corporation, Doha, Qatar, ⁴Histocompatibility & Immunogenetics Laboratory, Hamad Medical Corporation, Doha, Qatar
*Purpose: Virtual crossmatch (VXM) using Luminex single antigen bead has significantly improved prediction of an actual negative crossmatch. A negative crossmatch is typically required for…
2019 American Transplant Congress
Donor-Recipient HLA Mismatched Peptides Calculated by PIRCHE Algorithm Associate with De Novo Donor-Specific Cellular and Humoral Alloreactivity and Predicts Inferior Graft Outcome
M. Meneghini¹, E. Crespo², M. Niemann³, A. Torija², E. Melilli⁴, M. Jarque², N. Montero⁴, J. Cruzado¹, J. Grinyo¹, O. Bestard¹
¹Kidney Transplantation Unit, Bellvitge University Hospital- IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain, ²Experimental Nephrology Laboratory, IDIBELL, L'Hospitalet de Llobregat. Barcelona, Spain, ³PIRCHE AG, Berlin, Germany, ⁴Kidney Transplantation Unit, Bellvitge University Hospital, L'Hospitalet de Llobregat. Barcelona, Spain
*Purpose: PIRCHE-II algorithm predicts mismatched donor-derived HLA peptides number presented on recipient HLAclass-II molecules to recipient T-cells (indirect pathway of allorecognition) and has been associated…
2019 American Transplant Congress
Perioperative Blood Transfusion and Risk for Post-Transplant Sensitization and Rejection
A. Chung¹, M. Kleman¹, T. Pesavento¹, M. Abdel-Rasoul², R. Daloul¹
¹Internal Medicine, Division of Nephrology, The Ohio State University, Columbus, OH, ²Center for Biostatistics and Bioinformatics, The Ohio State University, Columbus, OH
*Purpose: Pre-transplant blood transfusion is a well-established risk factor for sensitization to human leukocyte antigens (HLA). HLA sensitization is associated with increased wait-list time, risk…
2019 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® (Anti-IL-6 Monoclonal) as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (nct03380962)
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, S. Williamsons, C. Myers, K. Lim, J. Choi, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Currently, there is growing interest in development of novel immune-modulatory drugs likely to improve allo-antibody reduction in transplantation. Clazakizumab (Vitaeris Inc.) is a humanized…